Abstract:Abstract: Alzheimer's disease (AD) is the most prevalent form of neurodegenerative disorder (ND), affecting more than 44 million individuals globally as of 2023. It is characterized by cognitive dysfunction and an inability to perform daily activities. The progression of AD is associated with the accumulation of amyloid beta (Aβ), the formation of neurofibrillary tangles (NFT), increased oxidative stress, neuroinflammation, mitochondrial dysfunction, and endoplasmic reticulum stress. Presently, various phytomedicines and their bioactive compounds have been identified for their neuroprotective effects in reducing oxidative stress, alleviating neuroinflammation, and mitigating the accumulation of Aβ and acetylcholinesterase enzymes in the hippocampus and cerebral cortex regions of the brain. However, despite demonstrating promising anti-Alzheimer's effects, the clinical utilization of phytoconstituents remains limited in scope. The key factor contributing to this limitation is the challenges inherent in traditional drug delivery systems, which impede their effectiveness and efficiency. These difficulties encompass insufficient drug targeting, restricted drug solubility and stability, brief duration of action, and a lack of control over drug release. Consequently, these constraints result in diminished bioavailability and insufficient permeability across the blood-brain barrier (BBB). In response to these challenges, novel drug delivery systems (NDDS) founded on nanoformulations have emerged as a hopeful strategy to augment the bioavailability and BBB permeability of bioactive compounds with poor solubility. Among these systems, nanoemulsion (NE) have been extensively investigated for their potential in targeting AD. NE offers several advantages, such as ease of preparation, high drug loading, and high stability. Due to their nanosize droplets, NE also improves gut and BBB permeability leading to enhanced permeability of the drug in systemic circulation and the brain. Various studies have reported the testing of NE-based phytoconstituents and their bioactives in different animal species, including transgenic, Wistar, and Sprague-Dawley (SD) rats, as well as mice. However, transgenic mice are commonly employed in AD research to analyze the effects of Aβ. In this review, various aspects such as the neuroprotective role of various phytoconstituents, the challenges associated with conventional drug delivery, and the need for NDDS, particularly NE, are discussed. Various studies involving phytoconstituent-based NE for the treatment of AD are also discussed.

Neuroprotective Potential of Aminonaphthoquinone Derivatives Against Amyloid Beta-Induced Neuronal Cell Death Through Modulation of SIRT1 and BACE1

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

A New Chiral Pyrrolyl α-Nitronyl Nitroxide Radical Attenuates β-Amyloid Deposition and Rescues Memory Deficits in a Mouse Model of Alzheimer Disease

Design and Synthesis of New Benzo[d]oxazole-Based Derivatives and Their Neuroprotective Effects on β-Amyloid-Induced PC12 Cells

Discovery of novel coumarin triazolyl and phenoxyphenyl triazolyl derivatives targeting amyloid beta aggregation-mediated oxidative stress and neuroinflammation for enhanced neuroprotection

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease <i>in vitro</i> and <i>in vivo</i>

7-(4-Hydroxyphenyl)-1-Phenyl-4e-Hepten-3-One, A Diarylheptanoid From Alpinia Officinarum, Protects Neurons Against Amyloid-Beta Induced Toxicity

In-vitro Neuro-2a cytotoxicity analysis and molecular docking investigation on potential anti-amyloid agents from Adiantum lunulatum

Neuroprotective Effects of AO-1 and AO-2 on Amyloid β-induced Cytotoxicity in SH-SY 5 Y Cells

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo

Novel 8-Hydroxyquinoline Derivatives Targeting Β-Amyloid Aggregation, Metal Chelation and Oxidative Stress Against Alzheimer's Disease.

Evaluation of Natural Flavonoid Compounds in Amyloid-β (Aβ) Inhibition for Alzheimer’s Disease Treatment

Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons

7-(4-Hydroxy-3-methoxyphenyl)-1-phenyl-4e-hepten-3-one Alleviates Aβ1-42 Induced Cytotoxicity Through PI3K-mTOR Pathways

Discovery of novel substituted (Z)-N'-hydroxy-3-(3-phenylureido)benzimidamide derivatives as multifunctional molecules targeting pathological hallmarks of Alzheimer's disease

Neuroprotective Role of Phytoconstituents-based Nanoemulsion for the Treatment of Alzheimer’s Disease

Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer’s Disease Therapy

Alleviation of Symptoms of Alzheimer's Disease by Diminishing Aβ Neurotoxicity and Neuroinflammation.

Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer's disease mouse model and proteomics analysis

Neuroprotective, Anti-Amyloidogenic and Neurotrophic Effects of Apigenin in an Alzheimer’s Disease Mouse Model

Exploring the Therapeutic Potential of Natural Compounds for Alzheimer's Disease: Mechanisms of Action and Pharmacological Properties.